Erasca, Inc. ERAS
13.76 USD -0.13 (-0.94%)
Regular-session close
14.15 +0.39 +2.83%
Pre-market · Nov 19, 4:01 AM ET
13.03 Day range 14.14
2.75 52-week range 24.28
- YTD
- +269.89%
- 1 year
- +381.12%
News
globenewswire.com Erasca Enters into Clinical Collaboration with Bristol Myers Squibb to Evaluate ERAS-0015 in Clinical Study with Navlimetostat ERAS-0015 will be evaluated with PRMT5 inhibitor navlimetostat in MTAP-deleted pancreatic cancer in Phase 1/2 trialbenzinga.com Leerink Partners Initiates Coverage On Erasca with Outperform Rating, Announces Price Target of $35 Leerink Partners initiates coverage on Erasca (NASDAQ:ERAS) with a Outperform rating and announces Price Target of $35.
globenewswire.com Erasca to Host Virtual Investor Event Highlighting Clinical Momentum Across Its RAS-Targeting Franchise SAN DIEGO, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for…
globenewswire.com Erasca Reports Third Quarter 2026 Business Updates and Financial Results ERAS-0015 granted FDA Fast Track Designation for metastatic pancreatic adenocarcinoma; advancing toward three potentially registration-enabling trials in pancreatic and lung cancers Updated ERAS-0015…
prnewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Erasca, Inc. - ERAS NEW YORK, Nov. 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Erasca, Inc. ("Erasca" or the "Company") (NASDAQ: ERAS). Such investors are advised to contact…
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers Revolution Medicines (NASDAQ:RVMD) stock rose 14.1% to $227.83 during Wednesday's after-market session. The market value of their outstanding shares is at $41.6 billion. As per the news, the…
